This website is intended exclusively for healthcare professionals and medical device manufacturers.
By accessing this site, you confirm that you belong to one of its of these categories and understand that the information provided is specifically intented for a professional audience.
"An approach that involves adding, replenishing, and correcting to achieve a form of medicine that regenerates, preserves, and optimizes biological processes."
Benoit Chardon is a global leader in aesthetic medicine, recognized for an exceptional career spanning the creation of new innovation categories and large-scale value creation.
Corporate value creation: Filorga: Created the brand and led the development of its skincare range before its acquisition by Colgate-Palmolive for $1.4 billion.
CoolSculpting: Led international marketing for this pioneering body-contouring platform, acquired by Allergan for $2.5 billion.
Allurion: As Chief Commercial Officer (CCO), increased revenue from $3 million to $65 million, leading to a listing on the New York Stock Exchange at a valuation of $500 million.
Fastox: Served as a board member and contributed to its acquisition by AbbVie.
Market-transforming innovations: Restylane Skinboosters shifted injectable treatments from volumization toward improved skin quality, creating a new therapeutic category. The relaunch of Sculptra repositioned biostimulation as a long-term regenerative strategy.
Recognition: Jury member for the IMCAS 2026 Innovation Awards and Chair of the AMWC 2026 Catalyst for Innovation.
Julien Vervel is a healthcare digital strategy expert recognized for his expertise in online visibility, medical branding, and digital strategy within the sector’s specific regulatory requirements.
Digital healthcare expertise: Managing Director of HEALTHCIE, an agency specializing in search engine optimization (SEO) and digital strategy for healthcare professionals and aesthetic surgery practices.
Innovation ecosystem: Recipient of French Tech Prépa 2020 and French Tech Incubation 2021 support; selected for the 2021 Digital Talents Directory.
Institutional engagements:Speaker at the French National Academy of Surgery, SFME, the Prague Lab congress, and AIME.
Digital strategy consultant for AbbVie, Pfizer, Vivacy, and Global D.
Presented by Dr. Jenny Doyle, The Clinic at Holland Park (United Kingdom)
Why it matters: Complementing HALO, Sciton’s BroadBand Light platform, featuring nine intelligent filters, a filter extending to 800 nm, fourfold speed, and threefold power, addresses pigmentary and vascular concerns. Its distinguishing feature is a rejuvenating effect demonstrated directly at the level of gene expression.
Scientific evidence: The Stanford study (Chang, Bitter et al., Journal of Investigative Dermatology, 2012) shows that BBL shifts the expression of 1,293 aging-related genes toward a younger profile, with skin perceived as nine years younger in blinded assessments. Combined with HALO TRIBRID, BBL HEROic targets skin uniformity and longevity.
Presented by Valentina Spada & Stephane Mendras (Switzerland)
Why it matters: Neauvia’s Dual Core Technology / Smart Crosslinking combines an immediate lifting effect (hyaluronic acid + PEG) with sustained regeneration (calcium hydroxylapatite / collagen) in a single injection.
Clinical impact: This single product eliminates the need for separate volumizing and biostimulatory products. PEG provides stability and reduces immunogenicity, combining the immediate lifting effect of conventional fillers with the durability of biostimulators.
Scientific evidence: Studies of the PEG-HA/CaHA system support its biocompatibility and activity in nasolabial folds and acne. The product received the AMWC 2024 award for Best Injectable Dermal Filler and the AMWC 2026 award for Most Disruptive Innovation.
Presented by Rahul Mehta, Co-Founder & CEO (United States)
Why it matters: Rapamycin, a key molecule in longevity research, carries risks when administered systemically. Rapalogix therefore developed RLX-201, a selective topical TORC1 inhibitor. It locally reduces skin aging and reactivates cellular self-repair without compromising the skin barrier.
Clinical impact: This treatment targets the biology of aging without systemic exposure to rapamycin. Unlike retinoids, which provide stimulation alone, RLX-201 acts through TORC1 to reset cells to a healthy, functional state before stimulation.
Scientific evidence: Preclinical research (Randhawa et al., Dermatologic Surgery, 2025; SID 2026) shows that RLX-201 selectively inhibits TORC1 while preserving TORC2, unlike rapamycin, and rejuvenates fibroblasts. Clinically, Re-Q Pro-Longevity Face Serum improves firmness and elasticity within two weeks, stimulates collagen and elastin at 12 weeks, and reverses biological skin age as assessed by epigenetic profiling.
Presented by Frédéric Flament, Medical Advisor (France), marketed under the Vichy brand
Why it matters: L’Oréal Research and Vichy demonstrate the efficacy of oral collagen through a precise amino acid ratio (glycine : proline : hydroxyproline) that directly targets collagen homeostasis and reduces biological age.
Clinical impact: This supplement extends the benefits of in-office procedures through a systemic, inside-out action that addresses overall aging and skin quality rather than an isolated wrinkle.
Scientific evidence: Findings published in npj Aging (2025) show that the formulation reduces biological age by 1.4 years (p = 0.04) at six months, with effects validated in C. elegans and fibroblasts. Four controlled trials confirm improvements in hydration, elasticity, and wrinkles within 12 weeks.
Presented by Nicole Simpson (United States)
Why it matters: In response to the instability of currently available exosome products, EMA Aesthetics is introducing BLŪPRIN: a standardized product focused on consistency, with traceable sourcing, guaranteed safety, and reproducible performance.
Clinical impact: This traceability and batch-to-batch reproducibility optimize safety and clinical efficacy through fully controlled mechanisms of action.
Scientific evidence: Presented at AMWC Monaco 2026, the product demonstrates manufacturing consistency. Available exclusively for topical cosmetic use in 2026, BLŪPRIN’s accumulating evidence is intended to support future FDA authorization.
Presented by Nidhi Bhola, VP of International Marketing (United Kingdom)
Why it matters: Hydrafacial standardizes treatment through its Vortex-Fusion technology, which simultaneously performs exfoliation, extraction, and infusion, ensuring a reproducible, operator-independent protocol. In 2026, the offering expands to scalp care with HydraScalp with Keravive.
Clinical impact: This rapid, no-downtime treatment supports patient retention. It is more reproducible than a manual treatment and more accessible than an energy-based device.
Scientific evidence: Freedman (2008) demonstrates increases in epidermal thickness (+58%), fibroblasts (+102%), and antioxidants (+51%). Other studies (Pep9 Booster, Storgard 2022) confirm improvements in firmness and hydration, together with a reduction in acne.
Why it matters: Conventional hydroxyapatite aggregates, forming nodules and precluding use in the infraorbital region. NanoSkinBio reduces its particle size to approximately 35 nm, enabling homogeneous dispersion and transdermal application using laser treatment or microneedling.
Clinical impact: The absence of aggregation enables treatment of high-risk areas, including the periorbital region, through injectable or transdermal administration, supported by optimized bioavailability and dispersion.
Scientific evidence: An in vitro study using BJ-5ta fibroblasts, submitted to the Journal of Cosmetic Dermatology in 2026, shows that nano-hydroxyapatite is noncytotoxic at concentrations up to 5% (v/v), compared with 2.5% for the microparticulate form. These findings and their clinical extrapolations still require in vivo confirmation.
Why it matters: Wonder Axon combines radiofrequency (RF) with neuromuscular stimulation (NMS). By treating the underlying muscular framework rather than the skin surface alone, it targets a key mechanism involved in aging and body composition.
Clinical impact: This platform treats both the face and body and is ideally suited to counteracting muscle loss associated with GLP-1 treatments. Its distinguishing features include independent optimization of RF and NMS, a protocol incorporating active recovery, reusable electrodes, and maximal muscle recruitment.
Scientific evidence: A cohort study (N = 60) following eight sessions demonstrates significant improvements (+8.3% muscle, −9.1% fat, −6.7% BMI, and +7.2% metabolism), with no serious adverse events. Its long-duration pulses, up to 1,000 μs, recruit type I and type II fibers, engaging 50% to 60% of the musculature.
Presented by Mojo Innovation AG (Switzerland), marketed under the EVOOIA brand
Evooia is an AI-assisted clinical photography solution that automatically standardizes before-and-after photographs in aesthetic medicine and plastic surgery. Through real-time guidance, it ensures reproducible images in terms of angle, distance, framing, and lighting, directly from a smartphone, while incorporating patient consent and secure documentation.
Target users: Plastic surgeons, aesthetic physicians, dermatologists, laser specialists, and multisite clinics seeking to objectively assess their results, improve patient communication, and standardize their clinical documentation.
Scientific evidence: A proprietary imaging protocol standardizes the four critical parameters of clinical photography: lighting, distance, angle, and patient positioning, ensuring reproducible images across visits, operators, and practice locations. Hosted in Switzerland and designed to meet GDPR and HIPAA requirements, its core technology is protected by a Swiss patent.
Presented by Synapse Medicine (France), marketed under the MedGPT brand
MedGPT is the first conversational medical artificial intelligence assistant developed in France exclusively for healthcare professionals.
Designed by Synapse Medicine, it answers clinical questions using more than 50 official French medical reference resources, providing sourced, traceable answers within seconds. Aligned with French medical reference standards, it aims to offer a sovereign alternative to general-purpose models.
Target users: Aesthetic physicians, plastic surgeons, dermatologists, and, more broadly, all healthcare professionals seeking rapid access to up-to-date recommendations, verification of medical information, or support for safer clinical decision-making.
Scientific evidence: Developed using more than 50 official medical reference resources, including HAS, ANSM, Thériaque, and INCa, MedGPT provides sourced, traceable, and regularly updated answers. The ASIMOV pilot study reports no major errors across 108 clinical questions assessed by three independent physicians, supporting the assistant’s relevance to medical practice.
By Dr. Fanny POIROT
By Dr. Mélissa Badof
By Dr. Jean-Jacques DEUTSCH
By Jonathan POTIER
By Dr. Alexandre KITIC & le Dr. Sarra CRISTOFARI
By Dr. Fanny POIROT
By Dr. Mélissa Badof
By Dr. Jean-Jacques DEUTSCH
By Jonathan POTIER
